📋 Athira Pharma, Inc. (ATHA) - Clinical Trial Update
Filing Date: 2022-10-17
Accepted: 2022-10-17 08:30:55
Event Type: Clinical Trial Update
Event Details:
Athira Pharma Inc (ATHA) Announces Clinical Trial Update
Athira Pharma Inc (ATHA) provided an update on its clinical development programs.
Clinical Development Highlights:
Clinical Stage: Phase 2, Clinical Study
Update Type: Trial Timeline Adjustment
Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
Collaboration: the Global Statistical Test
Updated Timeline: mid-2023, early 2024
targeting to complete enrollment in mid-2023
targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram. Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933
📋 Athira Pharma, Inc. (ATHA) - Clinical Trial Update
Filing Date: 2022-10-17
Accepted: 2022-10-17 08:30:55
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
Structured Data: